BioCentury
ARTICLE | Clinical News

Radius reports additional Phase I data for breast cancer candidate

December 15, 2017 4:36 PM UTC

Radius Health Inc. (NASDAQ:RDUS) reported additional data from the Phase I RAD1901-005 trial of elacestrant (RAD1901) in heavily pretreated, estrogen receptor-positive, HER2-negative patients with advanced breast cancer. Early next year, the company said it plans to start a “potentially pivotal” Phase II trial in estrogen receptor-positive, HER2-negative patients with advanced or metastatic breast cancer.

Among 22 evaluable postmenopausal patients treated in the trial’s first three parts, once-daily 400 mg oral elacestrant led to an objective response rate (ORR) of 27.3%, including six confirmed partial responses, plus eight cases of stable disease. Median progression-free survival (PFS) and median duration of response were 5.4 months and 17.4 weeks, respectively...

BCIQ Target Profiles

Estrogen receptor 1 (ESR1)